Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.16 Billion USD | 33.43% |
| 2022 | 875.5 Million USD | 20.48% |
| 2021 | 726.7 Million USD | -9.42% |
| 2020 | 802.3 Million USD | 25.18% |
| 2019 | 640.9 Million USD | 5.58% |
| 2018 | 607 Million USD | 9.39% |
| 2017 | 554.9 Million USD | 39.91% |
| 2016 | 396.6 Million USD | 16.68% |
| 2015 | 339.9 Million USD | 14.52% |
| 2014 | 296.8 Million USD | -3.92% |
| 2013 | 308.9 Million USD | 9.93% |
| 2012 | 281 Million USD | 7.54% |
| 2011 | 261.3 Million USD | 28.34% |
| 2010 | 203.6 Million USD | 22.72% |
| 2009 | 165.9 Million USD | 9.29% |
| 2008 | 151.8 Million USD | -0.52% |
| 2007 | 152.6 Million USD | 7.39% |
| 2006 | 142.1 Million USD | 8.06% |
| 2005 | 131.5 Million USD | 2.98% |
| 2004 | 127.7 Million USD | 5.98% |
| 2003 | 120.5 Million USD | 7.78% |
| 2002 | 111.8 Million USD | 28.51% |
| 2001 | 87 Million USD | 19.18% |
| 2000 | 73 Million USD | -56.8% |
| 1999 | 169 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.02 Billion USD | -15.12% |
| 2024 Q1 | 1.2 Billion USD | 3.35% |
| 2023 Q4 | 1.16 Billion USD | 13.15% |
| 2023 Q1 | 914.3 Million USD | 4.43% |
| 2023 Q2 | 980.2 Million USD | 7.21% |
| 2023 Q3 | 1.03 Billion USD | 5.33% |
| 2023 FY | 1.16 Billion USD | 33.43% |
| 2022 Q4 | 875.5 Million USD | 15.53% |
| 2022 Q3 | 757.8 Million USD | 2.41% |
| 2022 Q1 | 730.6 Million USD | 0.54% |
| 2022 Q2 | 740 Million USD | 1.29% |
| 2022 FY | 875.5 Million USD | 20.48% |
| 2021 Q2 | 759.5 Million USD | -1.09% |
| 2021 Q4 | 726.7 Million USD | -1.5% |
| 2021 FY | 726.7 Million USD | -9.42% |
| 2021 Q1 | 767.9 Million USD | -4.29% |
| 2021 Q3 | 737.8 Million USD | -2.86% |
| 2020 Q1 | 662.2 Million USD | 3.32% |
| 2020 Q2 | 735.1 Million USD | 11.01% |
| 2020 FY | 802.3 Million USD | 25.18% |
| 2020 Q4 | 802.3 Million USD | 3.75% |
| 2020 Q3 | 773.3 Million USD | 5.2% |
| 2019 Q1 | 630.9 Million USD | 3.94% |
| 2019 Q3 | 611.1 Million USD | -2.21% |
| 2019 FY | 640.9 Million USD | 5.58% |
| 2019 Q4 | 640.9 Million USD | 4.88% |
| 2019 Q2 | 624.9 Million USD | -0.95% |
| 2018 Q1 | 573.9 Million USD | 3.42% |
| 2018 FY | 607 Million USD | 9.39% |
| 2018 Q4 | 607 Million USD | 3.97% |
| 2018 Q2 | 568.1 Million USD | -1.01% |
| 2018 Q3 | 583.8 Million USD | 2.76% |
| 2017 Q2 | 491.6 Million USD | 13.95% |
| 2017 FY | 554.9 Million USD | 39.91% |
| 2017 Q4 | 554.9 Million USD | 3.06% |
| 2017 Q3 | 538.4 Million USD | 9.52% |
| 2017 Q1 | 431.4 Million USD | 8.77% |
| 2016 Q3 | 401 Million USD | 9.09% |
| 2016 Q1 | 356.6 Million USD | 4.91% |
| 2016 Q4 | 396.6 Million USD | -1.1% |
| 2016 FY | 396.6 Million USD | 16.68% |
| 2016 Q2 | 367.6 Million USD | 3.08% |
| 2015 Q3 | 333.5 Million USD | 6.45% |
| 2015 Q1 | 298.5 Million USD | 0.57% |
| 2015 FY | 339.9 Million USD | 14.52% |
| 2015 Q2 | 313.3 Million USD | 4.96% |
| 2015 Q4 | 339.9 Million USD | 1.92% |
| 2014 Q3 | 303.6 Million USD | -4.26% |
| 2014 Q1 | 308 Million USD | -0.29% |
| 2014 Q2 | 317.1 Million USD | 2.95% |
| 2014 FY | 296.8 Million USD | -3.92% |
| 2014 Q4 | 296.8 Million USD | -2.24% |
| 2013 Q2 | 299.5 Million USD | 3.81% |
| 2013 Q3 | 313.9 Million USD | 4.81% |
| 2013 Q4 | 308.9 Million USD | -1.59% |
| 2013 FY | 308.9 Million USD | 9.93% |
| 2013 Q1 | 288.5 Million USD | 2.67% |
| 2012 Q4 | 281 Million USD | -1.75% |
| 2012 FY | 281 Million USD | 7.54% |
| 2012 Q3 | 286 Million USD | 7.76% |
| 2012 Q2 | 265.4 Million USD | -1.08% |
| 2012 Q1 | 268.3 Million USD | 2.68% |
| 2011 FY | 261.3 Million USD | 28.34% |
| 2011 Q4 | 261.3 Million USD | 5.41% |
| 2011 Q3 | 247.9 Million USD | 8.06% |
| 2011 Q2 | 229.4 Million USD | 5.37% |
| 2011 Q1 | 217.7 Million USD | 6.93% |
| 2010 FY | 203.6 Million USD | 22.72% |
| 2010 Q2 | 182.3 Million USD | 4.41% |
| 2010 Q4 | 203.6 Million USD | -4.05% |
| 2010 Q3 | 212.2 Million USD | 16.4% |
| 2010 Q1 | 174.6 Million USD | 5.24% |
| 2009 Q4 | 165.9 Million USD | -1.66% |
| 2009 Q3 | 168.7 Million USD | 4.85% |
| 2009 Q1 | 146.1 Million USD | -3.75% |
| 2009 Q2 | 160.9 Million USD | 10.13% |
| 2009 FY | 165.9 Million USD | 9.29% |
| 2008 FY | 151.8 Million USD | -0.52% |
| 2008 Q1 | 139.5 Million USD | -8.58% |
| 2008 Q2 | 136.8 Million USD | -1.94% |
| 2008 Q3 | 143.8 Million USD | 5.12% |
| 2008 Q4 | 151.8 Million USD | 5.56% |
| 2007 Q4 | 152.6 Million USD | -3.6% |
| 2007 Q1 | 141.5 Million USD | -0.42% |
| 2007 Q2 | 143.5 Million USD | 1.41% |
| 2007 Q3 | 158.3 Million USD | 10.31% |
| 2007 FY | 152.6 Million USD | 7.39% |
| 2006 Q3 | 148.9 Million USD | 7.12% |
| 2006 FY | 142.1 Million USD | 8.06% |
| 2006 Q4 | 142.1 Million USD | -4.57% |
| 2006 Q2 | 139 Million USD | 2.96% |
| 2006 Q1 | 135 Million USD | 2.66% |
| 2005 Q2 | 131.3 Million USD | 4.12% |
| 2005 Q4 | 131.5 Million USD | -2.95% |
| 2005 Q3 | 135.5 Million USD | 3.2% |
| 2005 FY | 131.5 Million USD | 2.98% |
| 2005 Q1 | 126.1 Million USD | -1.25% |
| 2004 Q1 | 114.5 Million USD | -4.98% |
| 2004 Q2 | 119.5 Million USD | 4.37% |
| 2004 Q3 | 120.5 Million USD | 0.84% |
| 2004 Q4 | 127.7 Million USD | 5.98% |
| 2004 FY | 127.7 Million USD | 5.98% |
| 2003 Q4 | 120.5 Million USD | -3.83% |
| 2003 Q1 | 116.3 Million USD | 4.03% |
| 2003 Q2 | 125.6 Million USD | 8.0% |
| 2003 FY | 120.5 Million USD | 7.78% |
| 2003 Q3 | 125.3 Million USD | -0.24% |
| 2002 Q3 | 84.4 Million USD | -5.59% |
| 2002 Q4 | 111.8 Million USD | 32.46% |
| 2002 Q2 | 89.4 Million USD | 3.83% |
| 2002 Q1 | 86.1 Million USD | -1.03% |
| 2002 FY | 111.8 Million USD | 28.51% |
| 2001 FY | 87 Million USD | 19.18% |
| 2001 Q1 | 88.4 Million USD | 21.1% |
| 2001 Q4 | 87 Million USD | 7.81% |
| 2001 Q3 | 80.7 Million USD | 4.53% |
| 2001 Q2 | 77.2 Million USD | -12.67% |
| 2000 FY | 73 Million USD | -56.8% |
| 2000 Q4 | 73 Million USD | -6.89% |
| 2000 Q3 | 78.4 Million USD | -17.47% |
| 2000 Q2 | 95 Million USD | -39.1% |
| 2000 Q1 | 156 Million USD | -7.69% |
| 1999 Q4 | 169 Million USD | 0.0% |
| 1999 FY | 169 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Abbott Laboratories | 6.57 Billion USD | 82.219% |
| Allurion Technologies Inc. | 6.17 Million USD | -18830.481% |
| Artivion, Inc. | 81.97 Million USD | -1325.051% |
| Avanos Medical, Inc. | 163.2 Million USD | -615.809% |
| Butterfly Network, Inc. | 75.83 Million USD | -1440.409% |
| Butterfly Network, Inc. | 75.83 Million USD | -1440.409% |
| Bio-Rad Laboratories, Inc. | 780.51 Million USD | -49.67% |
| Boston Scientific Corporation | 2.48 Billion USD | 52.971% |
| Perspective Therapeutics, Inc. | 1.4 Million USD | -82809.865% |
| CONMED Corporation | 318.32 Million USD | -266.985% |
| Paragon 28, Inc. | 98.06 Million USD | -1091.287% |
| Glaukos Corporation | 41.98 Million USD | -2682.356% |
| Globus Medical, Inc. | 848.13 Million USD | -37.738% |
| Inspire Medical Systems, Inc. | 33.88 Million USD | -3347.543% |
| Integer Holdings Corporation | 239.71 Million USD | -387.327% |
| Medtronic plc | 5.21 Billion USD | 77.608% |
| Nevro Corp. | 118.67 Million USD | -884.361% |
| Owlet, Inc. | 6.49 Million USD | -17891.683% |
| Penumbra, Inc. | 388.02 Million USD | -201.065% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 2.39 Billion USD | 51.223% |
| Sonendo, Inc. | 11.07 Million USD | -10449.034% |
| STERIS plc | 674.53 Million USD | -73.186% |
| Stryker Corporation | 4.84 Billion USD | 75.879% |
| Vapotherm, Inc. | 22.96 Million USD | -4986.207% |
| Zimmer Biomet Holdings, Inc. | 2.38 Billion USD | 51.023% |